论文部分内容阅读
目的探讨美肠安治疗腹泻型肠易激综合征的疗效。方法将60例患者随机分为2组,A组30例,口服得舒特50 mg,每天3次。B组30例,口服美常安500 mg,每天3次,得舒特50 mg,每天3次,疗程4周。观察大便性状评分,腹部综合症状等级评分和疗效评价。结果治疗4周后,两组Bristol评分均较治疗前明显提高,腹部症状评分较治疗前都有明显下降,B组改善更明显。两组之间的治疗效果比较有明显差异,B组疗效更好。结论美肠安治疗腹泻型肠易激综合征安全有效。
Objective To investigate the clinical efficacy of MEIXA in treating diarrhea-predominant irritable bowel syndrome. Methods Sixty patients were randomly divided into two groups. Group A (n = 30) received Shutet 50 mg orally three times a day. Group B, 30 cases, the United States oral administration of 500 mg, 3 times a day, Shute 50 mg three times daily for 4 weeks. Observe the stool trait score, belly syndrome score and efficacy evaluation. Results After 4 weeks of treatment, the Bristol scores of both groups were significantly higher than those before treatment, and the scores of abdominal symptoms were significantly lower than those before treatment. The improvement of B group was more obvious. The treatment effect between the two groups was significantly different, B group better effect. Conclusions MEBO is safe and effective in treating diarrhea-predominant irritable bowel syndrome.